This week in Endocrinology
Nov 18, 2026
Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.
In 167 children aged six to under twelve with obesity, weekly semaglutide cut BMI by about 16 percentage points more than placebo at 68 weeks, with benefit sustained at two years.
New England Journal of Medicine · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: semaglutide is tested in children as young as six, tirzepatide is tested in adolescents, and a global cohort study puts the new definition of clinical obesity to the test.
Welcome to This Week in Endocrinology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
The New England Journal of Medicine published STEP Young, a phase 3, double-blind, placebo-controlled trial led by Jastreboff and colleagues in children aged six to under twelve with obesity [1]. A total of 167 children were randomized two to one to once-weekly subcutaneous semaglutide or placebo for 104 weeks, with lifestyle counselling in both groups and a seven-week washout at the end. At week 68, the primary endpoint, body-mass index fell by about 13 and a half percent with semaglutide and rose slightly with placebo, a between-group difference of about 16 percentage points. The gap held at two years, at close to 18 points. Almost four in five children on semaglutide moved down at least one BMI category, against under a quarter of children on placebo, and close to two in five children on semaglutide fell below the obesity threshold for age and sex. Gastrointestinal events were more common with semaglutide, but only one child stopped treatment because of them. The main limitation is scale: the trial is small, funded by the manufacturer, and two years is short for a drug that could be used across childhood. It is the first placebo-controlled phase 3 evidence for semaglutide below adolescence.
The same question one age band up was addressed in JAMA by SURMOUNT-ADOLESCENTS, led by Kelly [2]. This phase 3, double-blind trial randomized 160 adolescents aged 12 to under 18, with obesity or with overweight plus an obesity-related complication, at 31 centres in Canada, the Czech Republic, Israel, Italy, Poland and the United States. Mean BMI at baseline was close to 39. Tirzepatide, escalated to the maximum tolerated dose of up to 15 milligrams weekly, cut BMI by about 18 and a half percent at 72 weeks, while BMI rose slightly with placebo, a difference of about 19 percentage points. All ten key secondary outcomes favoured tirzepatide. Four in five adolescents on tirzepatide lost at least five percent of BMI, against under three in ten adolescents on placebo. Adverse events were mainly gastrointestinal and mostly mild to moderate. Limitations are a modest sample and an on-treatment window of 72 weeks without reported off-treatment follow-up. Alongside STEP Young, it extends randomized evidence for incretin-based drugs across the paediatric age range, with effect sizes of similar magnitude in the two trials.
In Nature, Pan and colleagues tested the Lancet Commission framework that separates clinical obesity, with adiposity-related organ dysfunction, from preclinical obesity, with preserved function [3]. They used data from 844,108 adults in four cohorts in China, the United Kingdom, the United States and Spain. Adding waist circumference and waist-to-height ratio to BMI showed that BMI alone missed obesity in roughly five to nine percent of participants, and the combined definition raised overall prevalence by several percentage points. Clinical obesity made up between a quarter and a third of all obesity. Most people with preclinical obesity, between about three quarters and nine in ten, did not progress to clinical obesity over ten years. Clinical obesity was associated with about 70 percent higher all-cause mortality, while preclinical obesity carried only a modest excess risk, and BMI-only obesity was not associated with higher mortality at all. The data are observational and the framework was applied retrospectively to cohorts with different measurements. The authors conclude the findings support global adoption of the framework, and this is the largest external validation of it so far.
Now, four in brief.
The Lancet Diabetes and Endocrinology published REDEFINE 9, a phase 3b trial led by Wharton testing lower doses of cagrilintide-semaglutide in 309 adults with obesity or overweight and no diabetes, at 24 sites in five countries [4]. Over 68 weeks, both the 1.7 milligram and the 1.0 milligram combination doses produced weight loss of about 21 percent, against about 2 percent with placebo. Around 95 percent of participants on either active dose lost at least five percent of body weight. Adverse events were mostly mild or moderate and gastrointestinal. The result is firm against placebo, though the population was more than three quarters female and the lower doses were not compared head to head with the higher dose.
A second incretin trial in JAMA, GEMINI-1, led by Zhao, tested ribupatide, a dual GIP and GLP-1 receptor agonist, in 567 adults without diabetes at 55 sites in China [5]. At 48 weeks, weight fell by about 11, 16 and 18 percent with the 2, 4 and 6 milligram doses, against just over one percent with placebo. Gastrointestinal events rose with dose, reaching about 63 percent of participants at the top dose, though under one percent of participants stopped treatment for adverse events. This is a large, well-conducted phase 3 trial, limited by its 48-week duration, a young population averaging 34 years, and enrolment in China only.
Turning to insulin delivery, Diabetologia published a multicentre randomized trial led by Moon in 120 adults with type 1 or type 2 diabetes on multiple daily injections at nine centres in South Korea [6]. Over 12 weeks, smart pens with an integrated bolus calculator lowered HbA1c by about 0.3 percentage points more than tracking-only connected pens, and time in range was about six points higher. Participants using smart pens missed fewer bolus doses, and no severe hypoglycaemia or ketoacidosis occurred in either group. The evidence is modest: the trial was small, open-label, short and industry-funded.
Nature Reviews Endocrinology published the primary aldosteronism imaging outcome consensus, an international multidisciplinary statement led by Völter [7]. It offers graded recommendations on CT, MRI and molecular imaging, covering what defines normal versus altered adrenal morphology, which abnormalities appear in lateralized and non-lateralized disease, and how reliably imaging predicts biochemical remission after unilateral adrenalectomy. It addresses how imaging can guide selection of patients for surgery. As expert consensus, its strength rests on the underlying studies it grades.
Three quick signals.
Also in Nature Reviews Endocrinology, Martens and colleagues review screening for early-stage type 1 diabetes, defined by two or more islet autoantibodies [8]. They compare high-risk and general-population strategies and describe how early identification can lower ketoacidosis risk at diagnosis, while cost-effectiveness and equitable follow-up remain unresolved. This is a narrative review.
In Endocrine Reviews, Hayes and colleagues review pituitary toxicity from immune checkpoint inhibitors [9]. The condition still lacks a validated biomarker or a single mechanism, with several plausible immune pathways that likely vary between patients. The authors set priorities for hormone replacement, education and long-term follow-up. This is a review without new data.
In the European Journal of Endocrinology, Liu, Liu and Rosen weigh romosozumab in people with cardiovascular disease [10]. Randomized trials conflict, meta-analyses have not excluded harm, and observational studies showing no excess risk are prone to selection bias. The authors judge the risk plausible but unproven and cite United States and European labeling excluding established cardiovascular disease. This is expert opinion.
Stepping back across this week's papers, the randomized evidence is concentrated on weight and body-mass index measured over one to two years of treatment, while the only data linking obesity categories to death came from observational cohorts. None of the new drug trials reports cardiovascular events, mortality or durability after stopping, and the paediatric trials are small. Bridging the gap between surrogate response and hard outcomes still depends on longer and larger studies.
If you only have time for one paper this week, make it the STEP Young trial of semaglutide in children aged six to under twelve [1]. It provides the first randomized phase 3 evidence for a GLP-1 receptor agonist in this age group and opens the question of how early pharmacotherapy for obesity belongs in childhood care.
That's your roundup for This Week in Endocrinology. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Endocrinology every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?